Overall survival from the EORTC LCG-1613 APPLE trial of osimertinib versus gefitinib followed by osimertinib in advanced EGFR-mutant non-small-cell lung cancer - Remon, J; Besse, B; Aix, S P (J Clin Oncol, 2024)